Politics · India Bureau
Alembic Pharma clears US FDA inspection at Vadodara facility
Alembic Pharmaceuticals has successfully passed an unannounced US Food and Drug Administration inspection at its bioequivalence testing facility in Vadodara, Gujarat, with no regulatory observations recorded.
LSN India ·
The pharmaceutical company announced on Friday that the USFDA concluded its onsite inspection of the Vadodara bioequivalence facility between August 31 and September 10, 2026, without issuing any Form 483 observations.
In regulatory terminology, the absence of Form 483 observations signifies a clean inspection outcome. The USFDA issues Form 483 notices when inspectors identify conditions that may violate the Food, Drug, and Cosmetic Act and related regulations. The zero-observation status indicates the facility met all applicable compliance requirements.
The company disclosed the inspection results through a regulatory filing, underscoring the facility's adherence to USFDA standards for bioequivalence testing. Bioequivalence facilities are critical to pharmaceutical development, as they conduct studies demonstrating that generic drugs perform equivalently to their brand-name counterparts.
This clearance strengthens Alembic Pharmaceuticals' regulatory standing in the US market, where bioequivalence certification is essential for generic drug approvals. The successful inspection outcome demonstrates the company's commitment to maintaining quality and compliance standards at its manufacturing and testing operations.